Non-cancer skin diseases (e.g., hyper-/hypo-pigmentation disorders linked to impaired melanin biosynthesis and tyrosinase activity), as well as malignant pathologies (e.g., melanoma), constitute promising research directions with cannabinoids, as recently reviewed by several authors [2,15,16,17]. The gene discussed is TYR; the disease is melanoma.